NCT06822517 - A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Parkinson Disease

Interventions

DRUG

VENT-02

Orally administered capsules

DRUG

Placebo

Orally administered capsules

Trial Locations (23)

19001

RECRUITING

Investigative Site, Abington

32117

RECRUITING

Investigative Site, Daytona Beach

32256

RECRUITING

Investigative Site, Jacksonville

32751

RECRUITING

Investigative Site, Maitland

32789

RECRUITING

Investigative Site, Winter Park

33067

RECRUITING

Investigative Site, Coral Springs

33134

RECRUITING

Investigative Site, Coral Gables

33135

RECRUITING

Investigative Site, Miami

33165

RECRUITING

Investigative Site, Miami

33178

RECRUITING

Investigative Site, Doral

33180

RECRUITING

Investigative Site, Aventura

33189

RECRUITING

Investigative Site, Cutler Bay

33486

RECRUITING

Investigative Site, Boca Raton

38157

RECRUITING

Investigative Site, Memphis

48334

RECRUITING

Investigative Site, Farmington Hills

77429

RECRUITING

Investigative Site, Cypress

78681

RECRUITING

Investigative Site, Round Rock

80113

RECRUITING

Investigative Site, Englewood

91307

RECRUITING

Investigative Site, West Hills

92708

RECRUITING

Investigative Site, Fountain Valley

95124

RECRUITING

Investigative Site, San Jose

99202

RECRUITING

Investigative Site, Spokane

04074

RECRUITING

Investigative Site, Scarborough

All Listed Sponsors

lead

Ventus Therapeutics U.S., Inc.

INDUSTRY